Terms: = Breast cancer AND EIF4A2, DDX2B, 1974, ENSG00000156976, EIF4F, BM-010, EIF4A AND Treatment
178 results:
1. Association of metastatic pattern in breast cancer with tumor and patient-specific factors: a nationwide autopsy study using artificial intelligence.
Kazemzadeh F; Snoek JAA; Voorham QJ; van Oijen MGH; Hugen N; Nagtegaal ID
Breast Cancer; 2024 Mar; 31(2):263-271. PubMed ID: 38133738
[TBL] [Abstract] [Full Text] [Related]
2. An update on rehabilitative treatment of shoulder disease after breast cancer care.
Ferrara PE; Gatto DM; Codazza S; Zordan P; Stefinlongo G; Ariani M; Coraci D; Ronconi G
Musculoskelet Surg; 2024 Mar; 108(1):31-45. PubMed ID: 38038901
[TBL] [Abstract] [Full Text] [Related]
3. Targeting eif4a triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N; Kabotyanski EB; Saltzman AB; Malovannaya A; Yuan X; Reineke LC; Lieu N; Gao Y; Pedroza DA; Calderon SJ; Smith AJ; Hamor C; Safari K; Savage S; Zhang B; Zhou J; Solis LM; Hilsenbeck SG; Fan C; Perou CM; Rosen JM
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37874652
[TBL] [Abstract] [Full Text] [Related]
4. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
Hemminki K; Försti A; Liska V; Kanerva A; Hemminki O; Hemminki A
Int J Cancer; 2023 May; 152(9):1837-1846. PubMed ID: 36571455
[TBL] [Abstract] [Full Text] [Related]
5. eif4a/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative breast cancer Cell Model.
González-Ortiz A; Pulido-Capiz A; Castañeda-Sánchez CY; Ibarra-López E; Galindo-Hernández O; Calderón-Fernández MA; López-Cossio LY; Díaz-Molina R; Chimal-Vega B; Serafín-Higuera N; Córdova-Guerrero I; García-González V
Cells; 2022 Dec; 11(24):. PubMed ID: 36552834
[TBL] [Abstract] [Full Text] [Related]
6. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
7. Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic breast cancer.
Li X; Beeghly-Fadiel A; Bhavnani SK; Tavana H; Rubinstein SM; Gyawali B; Riaz IB; Fernandes HD; Warner JL
JAMA Netw Open; 2022 Apr; 5(4):e224361. PubMed ID: 35416993
[TBL] [Abstract] [Full Text] [Related]
8. Effect of post-diagnosis exercise on depression symptoms, physical functioning and mortality in breast cancer survivors: A systematic review and meta-analysis of randomized control trials.
Salam A; Woodman A; Chu A; Al-Jamea LH; Islam M; Sagher M; Sager M; Akhtar M
Cancer Epidemiol; 2022 Apr; 77():102111. PubMed ID: 35091272
[TBL] [Abstract] [Full Text] [Related]
9. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.
Nagar H; Wietek N; Goodall RJ; Hughes W; Schmidt-Hansen M; Morrison J
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013021. PubMed ID: 34106467
[TBL] [Abstract] [Full Text] [Related]
10. A meta-analysis of the efficacy of vascularised lymph node transfer in reducing limb volume and cellulitis episodes in patients with cancer treatment-related lymphoedema.
Ward J; King I; Monroy-Iglesias M; Russell B; van Hemelrijck M; Ramsey K; Khan AA
Eur J Cancer; 2021 Jul; 151():233-244. PubMed ID: 34092349
[TBL] [Abstract] [Full Text] [Related]
11. Age as a risk factor for breast cancer-related lymphedema: a systematic review.
Guliyeva G; Huayllani MT; Boczar D; Avila FR; Lu X; Forte AJ
J Cancer Surviv; 2023 Feb; 17(1):246-253. PubMed ID: 33486706
[TBL] [Abstract] [Full Text] [Related]
12. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
[TBL] [Abstract] [Full Text] [Related]
13. eif4a Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in cancer.
Kong T; Xue Y; Cencic R; Zhu X; Monast A; Fu Z; Pilon V; Sangwan V; Guiot MC; Foulkes WD; Porco JA; Park M; Pelletier J; Huang S
Mol Cancer Ther; 2019 Nov; 18(11):2158-2170. PubMed ID: 31395685
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating eif4a2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract] [Full Text] [Related]
15. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Borchmann S; Joffe E; Moskowitz CH; Zelenetz AD; Noy A; Portlock CS; Gerecitano JF; Batlevi CL; Caron PC; Drullinsky P; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz AJ; Owens CN; Palomba ML; Younes A; Straus DJ
Blood; 2019 May; 133(20):2121-2129. PubMed ID: 30770396
[TBL] [Abstract] [Full Text] [Related]
16. Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).
Cuesta R; Berman AY; Alayev A; Holz MK
J Biol Chem; 2019 Feb; 294(7):2267-2278. PubMed ID: 30573685
[TBL] [Abstract] [Full Text] [Related]
17. Radiation therapy for malignant phyllodes tumor of the breast: An analysis of SEER data.
Kim YJ; Kim K
Breast; 2017 Apr; 32():26-32. PubMed ID: 28013032
[TBL] [Abstract] [Full Text] [Related]
18. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
Cuesta R; Holz MK
Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
[TBL] [Abstract] [Full Text] [Related]
19. Fresh frozen plasma for cardiovascular surgery.
Desborough M; Sandu R; Brunskill SJ; Doree C; Trivella M; Montedori A; Abraha I; Stanworth S
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD007614. PubMed ID: 26171897
[TBL] [Abstract] [Full Text] [Related]
20. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract] [Full Text] [Related]
[Next]
